A prospective single‐center, single‐arm, open‐label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer.
Saved in:
| Title: | A prospective single‐center, single‐arm, open‐label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer. |
|---|---|
| Authors: | Duan, Hongtao1 (AUTHOR), Wang, Zhaoyang1 (AUTHOR), Cao, Lili2 (AUTHOR), Zhu, Yifang1 (AUTHOR) zyfdht321@sina.com, Tong, Liping1 (AUTHOR) 281071642@qq.com, Yan, Xiaolong1 (AUTHOR) yanxiaolong@fmmu.edu.cn |
| Source: | Thoracic Cancer. Jul2024, Vol. 15 Issue 19, p1471-1476. 6p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17597706 |
|---|---|
| DOI: | 10.1111/1759-7714.15312 |
